The MODA trial is investigating new treatments for massive rotator cuff tears, which are a serious injury with a high risk of re-tear.[1] 72 patients between the ages of 18 and 65 were included in the study, who were randomly divided into two groups.[1] The first group received acellular dermal matrix (tissue without cells) alone, while the second group received this matrix enriched with bone marrow from the shoulder and tissue from the subacromial bursa (the pocket under the shoulder joint).[1] The primary goal of the study is to determine how many patients will have a re-tear within one year, as determined by an MRI scan.[1] Secondary objectives include assessment of patients' pain, function and quality of life over 12 months.[1] Researchers expect that combining mechanical augmentation with biological agents will improve tendon healing and reduce re-tears.[1] The advantage of the acellular dermal matrix used is that it is derived from human tissue and has lower production costs compared to commercially available products.[1]